Sanofi to acquire Ablynx for €3.9 billion

The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules


Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement, under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion.

The transaction was unanimously approved by both the Sanofi and Ablynx Boards of Directors. Olivier Brandicourt, CEO at Sanofi, said: “With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders.”

“This acquisition builds on a successful existing partnership. We are also pleased to reaffirm our commitment to Belgium, where we have invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel. We intend to maintain and support the Ablynx science center in Ghent.”

Edwin Moses, CEO at Ablynx, said: “Since our founding in 2001, our team has been focused on unlocking the power of our Nanobody technology for patients.  The results of our work are validated by clinical data. As we look ahead, we believe Sanofi's global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline.  Our Board of Directors feels strongly that this transaction represents compelling value for shareholders and maximizes the potential of our pipeline to the benefit of all stakeholders.”

Nanobodies are a novel class of proprietary next generation biologicals. Ablynx is at the leading edge of Nanobody technology supporting a deep pipeline of more than 45 proprietary and partnered candidates for a wide range of therapeutic areas such as hematology, inflammation, immuno-oncology and respiratory diseases. Eight Nanobodies have entered clinical development.

Sanofi is committed to accelerating development and maximising the commercial potential of Ablynx's ongoing and emerging programmes.

Companies